Strategic Research and Innovation Agenda
In its formative period, the JPIAMR under the guidance of its Scientific Advisory Board (SAB) and international stakeholders, developed a Strategic Research Agenda (SRA). The SRA defined six strategic and scientific priorities required to reduce antimicrobial resistance, improving public health and wellbeing of populations and delivering economic and societal benefits.
The JPIAMR recognises that innovation is critically important in the field of AMR, as there is a strong need for new therapeutics, diagnostics, and innovative infection prevention and intervention measures. In 2018, the JPIAMR updated the SRA to take account of recent research findings and extend the JPIAMR SRA into a Strategic Research and Innovation Agenda (SRIA). The updated SRIA was published in May 2019. It is hoped that this extension will support the participation of the private sector in JPIAMR research projects, and aid in the monitoring and evaluation of innovation management in funded research projects.
The updated priority topics of the SRIA are:
- Therapeutics: Discovery of new antibiotics and therapeutic alternatives, and the improvement of current antibiotics and treatment regimens.
- Diagnostics: Development and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics.
- Surveillance: Optimisation of surveillance systems to understand the drivers and burden of antimicrobial resistance in a One Health perspective.
- Transmission: Understanding and preventing the transmission of antimicrobial resistance.
- Environment: The role of the environment in the selection and spread of antimicrobial resistance.
- Interventions: Investigation and improvement of infection prevention and control measures in One Health settings.